CRISPR Therapeutics AG

🇺🇸NASDAQ Global Market
Back to all articles
CRISPR Therapeutics AG stock analysis CRSP overview
Neutral 0

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

📈 CRISPR Therapeutics (CRSP) shares have gained 1.4% over the past month, significantly underperforming the S&P 500's 11% gain and lagging its own industry's -1% movement.

🧬 The company is expected to post a quarterly loss of $1.11 per share, representing a +14% improvement compared to the same quarter last year.

📉 Consensus earnings estimates for the current fiscal year stand at -$5.07, while the next year's projection shows a turnaround to $4.35.

💰 Revenue growth is projected to be explosive in the short term, with current quarter estimates pointing to an 818.8% increase year-over-year.

📊 Actual revenue reported for the last quarter was $1.46 million, which missed the consensus estimate by -82.62%.

🤖 The Zacks Rank tool has assigned CRSP a rating of #3 (Hold), suggesting the stock may perform in line with the broader market in the near term.

💸 The company carries an F-grade on the Zacks Value Style Score, indicating it is currently trading at a premium valuation relative to its peers.

🔄 Analyst estimates for the current quarter have increased by 5.9% over the last 30 days, while full-year earnings forecasts have dipped slightly.

⚠️ Historical performance shows the company beat EPS expectations twice in the last four quarters but failed to meet consensus revenue estimates during that same period.

📈 The forward 12-month consensus EPS estimate is projected to grow by +14.2% from the prior year's figures.

🔍 Zacks emphasizes that future stock performance is determined more by fundamental factors like earnings revisions than by short-term media trends or rumors.

🏆 Despite a positive shift in loss estimates, the current valuation multiples suggest the stock remains expensive compared to the biomedical and genetics industry peers.

Bullish Signals
  • CRISPR Therapeutics reported revenues of $1.46 million in the last reported quarter, representing a year-over-year change of +67.8%.
  • EPS of -$1.28 for the same period compares favorably to -$1.58 a year ago, indicating an improvement in profitability despite the loss.
  • For the current quarter, earnings estimates are expected to be -$1.11 per share, which indicates a positive change of +14% from the year-ago quarter.
  • The consensus earnings estimate for the current fiscal year shows a strong year-over-year growth projection of +21.6%.
  • Revenue forecasts for the next fiscal year indicate a significant potential increase of +274.1% compared to current projections.
  • Over the last four quarters, the company has surpassed consensus EPS estimates two times and topped revenue estimates multiple times during this period.
Risk Factors
  • The stock has underperformed the broader market, losing $0.9% relative to the S&P 500 while the overall index gained +11% over the past month.
  • Earnings estimates are facing downward pressure, with recent revisions showing a -2.7% decline for the next fiscal year and a -3.5% drop for the current fiscal year over the last 30 days.
  • The company received a Zacks Rank #3 (Hold), indicating that it is expected to perform only in line with the broader market rather than outperforming.
  • Valuation metrics are concerning, as CRSP has received an 'F' grade on its Value Style Score, suggesting it is trading at a premium to its peers.
  • The most recent quarterly revenue of $1.46 million significantly missed the consensus estimate of $8.39 million by -82.62%, and EPS also missed estimates by -12.28%.
  • Despite positive long-term growth projections, the high valuation and current lack of consistent profitability (loss of $1.11 per share this quarter) create risks for near-term performance.
Full Analysis
CRISPR Therapeutics AG, trading under the ticker CRSP, is currently identified as a trending stock on Zacks.com following increased search volume and market attention. The article analyzes the stock's recent performance, noting that shares rose 1.4% over the past month compared to an 11% gain for the S&P 500 composite and contrasting this with the biotechnology industry's 1% decline. While acknowledging that media rumors often drive short-term trends, the content emphasizes that fundamental factors and future earnings projections are more relevant for long-term investment decisions, specifically citing the Zacks methodology which links earnings estimate revisions to stock fair value. The article provides specific financial estimates and actual performance data, highlighting that CRSP is expected to incur a loss of $1.11 per share for the current quarter, representing a 14% improvement from the year-ago quarter. Analyst consensus estimates show significant projected growth, with full-year earnings expected at -$5.07 (a 21.6% increase) and next fiscal year earnings projected at $4.35 (a 14.2% increase). Revenue projections are particularly steep, with current quarter sales estimated at $8.18 million, which represents an 818.8% year-over-year growth rate, compared to actual reported revenues of $1.46 million in the last quarter, a 67.8% increase that missed estimates by approximately 83%. Valuation metrics are also scrutinized, with the company receiving a Zacks Value Style Score of F, indicating it trades at a significant premium relative to its peers. This premium is attributed to high price-to-earnings and other valuation multiples. Despite the high growth expectations in revenue and earnings revisions, the analysis concludes that the stock holds a Zacks Rank of 3 (Hold), suggesting that while fundamental trends are positive, the near-term price performance is likely to track with the broader market rather than experience an immediate outperformance.